Strides Arcolab gets USFDA approval for cancer drug unit

Drug firm Strides Arcolab today said it has received the US health regulator's approval for its oncology facility in Bangalore.

Onco Therapies Ltd, a division of Agila which is a wholly owned subsidiary of the company, has received US Food and Drug Administration (USFDA) approval for its oncology facility, Strides Arcolab said in a statement.

Commenting on the approval, Agila Specialties CEO Venkat Iyer said: "With this approval and the recently announced approval for the sterile complex, we now look forward to scaling up our specialty business through the launch of highly specialised products for the US market."

The company recently received USFDA approval for its sterile facility (non-oncology) in Bangalore. With these approvals, all of Strides' five sterile plants in India are now USFDA approved, it said.

Agila is the specialties unit of Strides Arcolab which was spun off into a separate division post the company's restructuring in 2009.

The Bangalore facility was established in 2009 and manufactures injectables, oral products (tablets and softgels) in the oncology domain.

"This approval is an important step in strengthening our specialty business and intent to be a global sterile powerhouse," Strides Arcolab Vice-Chairman & Group CEO Arun Kumar said.

USFDA approval for the new facility will give impetus to the company's collaborations with global pharma companies, including Pfizer and GlaxoSmithKline.

In January, 2010, the company had announced a licencing and supply collaboration with Pfizer Inc on 40 generic products for the US market.

The Bangalore-based firm said it expects to commercialise its first oncology product for the US market in the beginning of the second half of 2011.

Further, in May, 2010, the company extended its partnership with Pfizer Inc by extending the oncology agreement to Europe, Canada, Australia, New Zealand, Japan and Korea for 38 generic oncology products.

image
Business Standard
177 22
Business Standard

Strides Arcolab gets USFDA approval for cancer drug unit

Press Trust of India  |  New Delhi 



Drug firm Strides Arcolab today said it has received the US health regulator's approval for its oncology facility in Bangalore.

Onco Therapies Ltd, a division of Agila which is a wholly owned subsidiary of the company, has received US Food and Drug Administration (USFDA) approval for its oncology facility, Strides Arcolab said in a statement.

Commenting on the approval, Agila Specialties CEO Venkat Iyer said: "With this approval and the recently announced approval for the sterile complex, we now look forward to scaling up our specialty business through the launch of highly specialised products for the US market."

The company recently received USFDA approval for its sterile facility (non-oncology) in Bangalore. With these approvals, all of Strides' five sterile plants in India are now USFDA approved, it said.

Agila is the specialties unit of Strides Arcolab which was spun off into a separate division post the company's restructuring in 2009.

The Bangalore facility was established in 2009 and manufactures injectables, oral products (tablets and softgels) in the oncology domain.

"This approval is an important step in strengthening our specialty business and intent to be a global sterile powerhouse," Strides Arcolab Vice-Chairman & Group CEO Arun Kumar said.

USFDA approval for the new facility will give impetus to the company's collaborations with global pharma companies, including Pfizer and GlaxoSmithKline.

In January, 2010, the company had announced a licencing and supply collaboration with Pfizer Inc on 40 generic products for the US market.

The Bangalore-based firm said it expects to commercialise its first oncology product for the US market in the beginning of the second half of 2011.

Further, in May, 2010, the company extended its partnership with Pfizer Inc by extending the oncology agreement to Europe, Canada, Australia, New Zealand, Japan and Korea for 38 generic oncology products.

RECOMMENDED FOR YOU

Strides Arcolab gets USFDA approval for cancer drug unit

Drug firm Strides Arcolab today said it has received the US health regulator's approval for its oncology facility in Bangalore.

Drug firm Strides Arcolab today said it has received the US health regulator's approval for its oncology facility in Bangalore.

Onco Therapies Ltd, a division of Agila which is a wholly owned subsidiary of the company, has received US Food and Drug Administration (USFDA) approval for its oncology facility, Strides Arcolab said in a statement.

Commenting on the approval, Agila Specialties CEO Venkat Iyer said: "With this approval and the recently announced approval for the sterile complex, we now look forward to scaling up our specialty business through the launch of highly specialised products for the US market."

The company recently received USFDA approval for its sterile facility (non-oncology) in Bangalore. With these approvals, all of Strides' five sterile plants in India are now USFDA approved, it said.

Agila is the specialties unit of Strides Arcolab which was spun off into a separate division post the company's restructuring in 2009.

The Bangalore facility was established in 2009 and manufactures injectables, oral products (tablets and softgels) in the oncology domain.

"This approval is an important step in strengthening our specialty business and intent to be a global sterile powerhouse," Strides Arcolab Vice-Chairman & Group CEO Arun Kumar said.

USFDA approval for the new facility will give impetus to the company's collaborations with global pharma companies, including Pfizer and GlaxoSmithKline.

In January, 2010, the company had announced a licencing and supply collaboration with Pfizer Inc on 40 generic products for the US market.

The Bangalore-based firm said it expects to commercialise its first oncology product for the US market in the beginning of the second half of 2011.

Further, in May, 2010, the company extended its partnership with Pfizer Inc by extending the oncology agreement to Europe, Canada, Australia, New Zealand, Japan and Korea for 38 generic oncology products.

image
Business Standard
177 22
Widgets Magazine

More News

  • Drug pricing norms outdated, must be amended: NPPA chief Drug pricing norms outdated, must be amended: NPPA chief
  • Pankaj Oswal and his father, Abhey Oswal Oswal group initiates sale of NDTV stake at 3.5 times returns
Widgets Magazine
Widgets Magazine

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard